Rifamycin

{{DrugProjectFormSinglePage |authorTag=Kiran Singh, M.D. [1] |aOrAn=a |adverseReactions= |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

• Content

|fdaLIADAdult======Condition1=====

• Dosing Information

• Dosage

Condition2

• Dosing Information

• Dosage

Condition3

• Dosing Information

• Dosage

Condition4

• Dosing Information

• Dosage

|offLabelAdultGuideSupport======Condition1=====

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Rifamycin in adult patients.

|offLabelAdultNoGuideSupport======Condition1=====

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rifamycin in adult patients.

|fdaLIADPed======Condition1=====

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Rifamycin in pediatric patients.

|offLabelPedGuideSupport======Condition1=====

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Rifamycin in pediatric patients.

|offLabelPedNoGuideSupport======Condition1=====

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rifamycin in pediatric patients.

|contraindications=* Condition1

|warnings=* Description

Precautions

• Description

|clinicalTrials=There is limited information regarding Clinical Trial Experience of Rifamycin in the drug label.

Miscellaneous

|postmarketing=There is limited information regarding Postmarketing Experience of Rifamycin in the drug label.

Miscellaneous

|drugInteractions=* Drug

• Description

|useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Rifamycin in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Rifamycin during labor and delivery. |useInNursing=There is no FDA guidance on the use of Rifamycin with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Rifamycin with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Rifamycin with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Rifamycin with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Rifamycin with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Rifamycin in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Rifamycin in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Rifamycin in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Rifamycin in patients who are immunocompromised.

|administration=* Oral

• Intravenous

|monitoring=There is limited information regarding Monitoring of Rifamycin in the drug label.

• Description

|IVCompat=There is limited information regarding IV Compatibility of Rifamycin in the drug label.

|overdose====Acute Overdose===

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Rifamycin in the drug label.

|drugBox= |mechAction=*

|structure=Rifampin capsules, USP for oral administration contain 150 mg or 300 mg rifampin per capsule. The 150 mg and 300 mg capsules also contain, as inactive ingredients: colloidal silicon dioxide, corn starch, FD&C Blue No. 1, FD&C Red No. 40, gelatin, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, talc, and titanium dioxide.

The printing ink contains ammonium hydroxide, isopropyl alcohol, n-butyl alcohol, pharmaceutical glaze, propylene glycol, simethicone, and titanium dioxide

Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight is 822.95 and its chemical formula is C43H58N4O12.

The chemical name for rifampin is either:

3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin

or 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate.

Its structural formula is:

This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Rifamycin in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Rifamycin in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Rifamycin in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Rifamycin in the drug label.

|howSupplied=* |packLabel= |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Rifamycin in the drug label.

|alcohol=* Alcohol-Rifamycin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=* ®

|lookAlike=* A® — B®

|drugShortage= }} {{#subobject:

 |Page Name=Rifamycin
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Rifamycin
 |Label Name=Rifamycin11.png

}}

{{#subobject:

 |Label Page=Rifamycin
 |Label Name=Rifamycin11.png

}}